ERBB2 and neoplasm: One patient with ERBB2 AMP and concomitant CNAs of genes in HER2 DPs achieved a durable response to trastuzumab deruxtecan as fourth-line therapy.<h4>Conclusions</h4>A targeted tumour sequencing test is a reliable modality for identifying HER2-positive GC.